The U.S. Food and Drug Administration on Monday authorized the emergency use of Abbott Laboratories’ coronavirus test for detecting antibodies using another of its diagnostic platforms, which will allow the company to ship nearly 30 million tests this month.
Earlier, the company had permission to run the antibody test on its Architect platform. The authorization now allows Abbott to use the test on its Alinity platform.
Abbott also said it could have capacity for shipping 60 million antibody tests across the world in June, which included tests on its Architect system, for which it gained authorization last month. Alinity systems are designed to run more tests in less space and minimize human errors, Abbott said.
The test identifies disease-fighting antibodies in people who have been infected but may have had mild symptoms or none at all, making it different from the current diagnostic tests that require nasal swabs to confirm active infection.